Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02979366 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome
A Phase 1 study, sponsored by Institut de Recherches Internationales Servier.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT02979366 is a Phase 1 study that has completed, run by Institut de Recherches Internationales Servier. The registered enrollment target is 38 participants.
The verdict
NCT02979366, a Phase 1 study, has completed, sponsored by Institut de Recherches Internationales Servier.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The CL1-64315-001 study is a phase I, international, multicentre, open-label, non-randomised, non-comparative study. This study is designed in two parts: one part for dose escalation, one part for dose expansion.
Interventions
- DRUG S64315 once a week
- DRUG S64315 twice a week
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2020-05-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02979366
The ClinicalTrials.gov registry entry for NCT02979366 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institut de Recherches Internationales Servier, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which S64315 once a week is the first listed.
NCT02979366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02979366 about?
NCT02979366 is a clinical study titled "Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome". The CL1-64315-001 study is a phase I, international, multicentre, open-label, non-randomised, non-comparative study. This study is designed in two parts: one part for dose escalation, one part for dose expansion.
What is the current status of trial NCT02979366?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2017-03-15. Estimated completion is 2020-05-11.
What interventions are being tested in trial NCT02979366?
The interventions under investigation include: S64315 once a week (DRUG), S64315 twice a week (DRUG).
Who is sponsoring clinical trial NCT02979366?
This trial is sponsored by Institut de Recherches Internationales Servier, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.